[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lupus-erythematosus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lupus-erythematosus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,89,116,149,174,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100327492","phase-4-trial-of-belimumab-in-early-lupus-100327492",false,"NCT03543839","Trial of Belimumab in Early Lupus","Pilot Trial of Belimumab in Early Lupus","Inclusion Criteria:\n\n* Diagnosis of SLE per current ACR classification criteria\n* Date of SLE diagnosis within 2 years of screening\n* ANA positive (with a titer ≥ 80)\n* anti-ds DNA antibody positive\n* Mild to moderate disease activity define by a SLEDAI-2K ≥4\n* Stable corticosteroid dose in the 4 weeks prior to screening ≤ 30mg\u002Fday.\n* If on methotrexate, dose must be stable for 4 weeks\n* Concomitant treatment with hydroxychloroquine unless documented inability to tolerate\n* Able and willing to give written informed consent and comply with the requirements of the study protocol\n* Negative serum pregnancy test (for women of child bearing potential)\n* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for 16 weeks after completion of treatment\n\nExclusion Criteria:\n\n* Previous exposure to disease modifying drugs such as azathioprine, mycophenolate mofetil, cyclophosphamide, or cyclosporine.\n* Previous exposure to biologic therapies including rituximab, belimumab or other agents that have been investigated for SLE.\n* Active renal or nervous system disease or disease activity fulfilling BILAG A criteria\n* Use of high dose steroids (\\>0.5 mg\u002Fkg\u002F day) within the 4 weeks prior to screening\n* Expectation (by the investigator) that the subject will require treatment with a disease modifying drug within the first 52 weeks of the study\n* Hemoglobin: \\\u003C 8.0 gm\u002FdL\n* Platelets: \\\u003C 50,000\u002Fmm\n* ANC \\\u003C 1.0 x 103\u002Fmm\n* AST or ALT \\>2.5 x Upper Limit of Normal unless related to primary disease.\n* Creatinine clearance ≤ 25ml\u002Fmin per 1.73 m2\n* Positive Hepatitis B or C serology (Hep B Surface antigen, Hep B core Ab or Hepatitis C antibody)\n* History of positive HIV (HIV conducted during screening if applicable)\n* Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)\n* Receipt of a live vaccine within 30 days prior to baseline or concurrently with belimumab\n* Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies\n* Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria)\n* Hospitalization for treatment of infection within 60 days of Day 0.\n* Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day 0\n* History of serious recurrent or chronic infection\n* Lack of peripheral venous access\n* History of drug, alcohol, or chemical abuse within 365 days prior to Day 0\n* Pregnancy (a negative serum pregnancy test must be obtained for all women of childbearing potential at screening; a urine pregnancy test must be negative \\\u003C 7 days prior to first dose and monthly)\n* Lactation\n* History of psychiatric disorder that would interfere with normal participation in this protocol\n* Significant cardiac or pulmonary disease (including obstructive pulmonary disease)\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n* History of malignant neoplasm within the last 5 years with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* Evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and\u002For any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk\n* History of a primary immunodeficiency\n* Have a significant IgG deficiency (IgG level \\\u003C 400 mg\u002FdL)\n* Have an IgA deficiency (IgA level \\\u003C 10 mg\u002FdL)\n* Have any other clinically significant abnormal laboratory value in the opinion of the investigator\n* Comorbidities requiring corticosteroid therapy, including those which have required two or more courses of systemic courses of systemic corticosteroids within the previous 12 months\n* Inability to comply with study and follow-up procedures","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab will be rerandomized to continue to receive belimumab or to receive placebo. The study will look at clinical effects as well as effects on the immune system.",[26,27],"Lupus Erythematosus, Systemic","Lupus Erythematosus",[29,30,31,32],"lupus","early lupus","belimumab","autoreactivity","RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2020-09-15",{"date":41,"type":20},"2029-03",{"name":43,"class":44},"Northwell Health","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":45},"100592874","teams-engaged-in-accessible-mental-health-interventions-for-lupus-erythematosus-and-dermatomyositis-stress-100592874","NCT06999109","Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress","TEAM-LEADS","Inclusion Criteria:\n\n* Diagnosis of juvenile-onset systemic lupus erythematosus (JSLE) or dermatomyositis (JDM)\n* Age 13-22 years old at time of enrollment\n\nExclusion Criteria:\n\n* Inability to complete surveys\u002Finterviews reliably\n* Lack of access to internet-enabled device;\n* Non-JSLE\u002FJDM diagnosis\n* History of myocardial infarction or cerebrovascular accident\n* Evidence of severe emotional distress defined as any of the following at time of screening: a) Patient Health Questionnaire for Adolescents (PHQ9A) score ≥ 15 indicating severe depression; b) PHQ9A suicidality item score \\> 0 indicating presence of any suicidal ideation; c) any other evidence noted of severe emotional distress per PI's judgment.","13 Years","22 Years",{"count":56,"type":20},25,[58],"NA","The objectives of this study are to determine if the 'Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress' (TEAM-LEADS) intervention is feasible and acceptable to adolescents and young adults with lupus and dermatomyositis and whether it can help reduce stress and promote cardiovascular health behaviors in these individuals.",[61,62,63,27,26,64],"Lupus","Dermatomyositis, Juvenile","Dermatomyositis","Lupus or SLE",[66,67,68,61,63,69,70,71,72,73,74,75,76,77,78],"Stress","Depression","Anxiety","Pediatric Rheumatology","Physical Activity","Diet Quality","Sleep","Cardiovascular Health","Health Behaviors","Remote Intervention","Online Intervention","Co-Design","Intervention Refinement","NOT_YET_RECRUITING","2026-05-22",{"date":82,"type":37},"2026-05-27",{"date":84,"type":20},"2027-02-01",{"date":86,"type":20},"2029-01-15",{"name":88,"class":44},"Duke University",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100630120","identification-of-modifiable-sleep-related-factors-in-patients-with-systemic-lupus-erythematosus-100630120","NCT07483541","Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.","Inclusion Criteria:\n\n* Adults aged ≥18 years;\n* A medical diagnosis of systemic lupus erythematosus (according to current clinical classification criteria);\n* Both sexes;\n* Clinically stable condition during the previous 3 months; and\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Individuals whose usual occupation involves night or rotating shift work;\n* A previous diagnosis of a primary sleep disorder receiving specific treatment (e.g., severe obstructive sleep apnea treated with CPAP, narcolepsy, or other central sleep disorders); and\n* Psychiatric or cognitive impairment that may prevent or substantially limit the accurate completion of the questionnaires",{"count":96,"type":20},250,"OBSERVATIONAL","Background: Sleep quality is a key determinant of physical and mental health, with important implications for immune regulation, psychological well-being, and overall quality of life. In systemic lupus erythematosus (SLE), sleep disturbances are highly prevalent and have been associated with poorer clinical and psychosocial outcomes. However, the specific contribution of potentially modifiable behavioral and environmental factors to sleep quality in this population has been insufficiently investigated.\n\nObjectives: To analyze the association between modifiable lifestyle, behavioral, and environmental factors and sleep quality in adults with systemic lupus erythematosus.\n\nMethods: A multicenter cross-sectional observational study will be conducted. Approximately 250 adults with systemic lupus erythematosus from different regions of Spain will be included. The primary outcome will be sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI). Independent variables will include physical activity (International Physical Activity Questionnaire-Short Form), substance use, sleep timing and regularity, napping habits, screen exposure, and bedroom environmental conditions. Secondary variables will include risk of obstructive sleep apnea (STOP-Bang questionnaire), daytime sleepiness (Epworth Sleepiness Scale), perceived stress (Perceived Stress Scale-10), as well as clinical, sociodemographic, and anthropometric variables.\n\nExpected results: To identify behavioral and environmental factors independently associated with poor sleep quality in individuals with systemic lupus erythematosus and to estimate the prevalence of poor sleep quality in the study sample.",[27],[101,102,103,104,105],"Systemic lupus erythematosus","Sleep quality","Sleep hygiene","Lifestyle","Physical activity","2026-04-28",{"date":108,"type":37},"2026-05-04",{"date":110,"type":20},"2026-05-05",{"date":112,"type":20},"2026-07-25",{"name":114,"class":115},"Investigación en Hemofilia y Fisioterapia","NETWORK",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":128,"conditions":129,"keywords":134,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":45},"100458576","clinico-biological-collection-to-investigate-the-physiopathology-of-systemic-autoimmune-diseases-100458576","NCT05251415","Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases","Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Pathophysiological Investigations of Systemic Autoimmune Diseases","ESSAi","Inclusion Criteria:\n\n* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),\n* Patients with atypical presentations of documented or probable systemic autoimmune diseases,\n* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).\n\nExclusion Criteria:\n\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","6 Years","99 Years",{"count":127,"type":20},3000,"The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies",[27,130,131,132,133],"Scleroderma","Myositis","Vasculitis","Inflammatory Bowel Diseases",[135,136,29,137,138,133,139],"systemic autoimmune diseases","scleroderma","myositis","vasculitis","new therapies","2026-03-16",{"date":142,"type":37},"2026-03-17",{"date":144,"type":37},"2022-04-04",{"date":146,"type":20},"2032-04-04",{"name":148,"class":44},"University Hospital, Toulouse",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":45},"100153261","cutaneous-lupus-registry-100153261","NCT01266915","Cutaneous Lupus Registry","Molecular Studies on Cutaneous Lupus","Inclusion Criteria:\n\n* Diagnosed with cutaneous lupus erythematosus and\u002For systemic lupus erythematosus by clinical, laboratory, and histopathological findings\n* Ability to speak and read English or Spanish at a 6th grade reading level (a translator will be available with additional consent forms in Spanish)\n* Ability to give written informed consent\n\nExclusion Criteria:\n\n* Less than 18 years of age, since the characteristics of the disease in these subjects could be very different\n* Due to a medication, in which its discontinuation results in the resolution of cutaneous lupus, since the characteristics of the disease in these subjects could be very different\n* Medical conditions who do not warrant a skin biopsy\n* Unable to give written, informed consent or undergo a skin biopsy and\u002For venipuncture for any other reason",true,{"count":158,"type":20},1000,"Approximately 1.4 million individuals in the United States have systemic lupus erythematosus, and about 85% of these individuals develop skin lesions at some point of their disease. Cutaneous lupus erythematosus represents the skin manifestations of systemic lupus erythematosus, and can appear in people with or without systemic lupus. It is a mentally, physically, and emotionally debilitating disease that affects both the quality of life and social well-being of those affected.\n\nThe cause of cutaneous lupus is not completely understood, but likely includes multiple factors from our genes and the environment. Multiple genetic studies with small numbers of cutaneous lupus patients have been performed to determine which genes are associated with cutaneous lupus. This study aims to accumulate even larger numbers of patients to confidently identify genes and the proteins they encode that could contribute greatly to the formation of cutaneous lupus. The discovery of these genes and proteins would help not only uncover how cutaneous lupus forms, but also improve our abilities to diagnose this disease and predict its course, and stimulate new drug development.",[27],[162,163,164],"SCLE","CLE","DLE","2025-11-20",{"date":167,"type":37},"2025-11-26",{"date":169,"type":4},"2009-01",{"date":171,"type":20},"2030-12",{"name":173,"class":44},"University of Texas Southwestern Medical Center",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":156,"sex":182,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":196,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":45},"100548847","the-role-of-cytokines-and-regulatory-t-lymphocytes-in-migraine-pathophysiology-100548847","NCT06426316","The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.","Immune System, Inflammation, Migraine - The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology","SIIM","Inclusion Criteria:\n\n* female\n* 18 - 50 years of age\n* at least 50 kg\n* autoimmune\u002Finflammatory disease groups : with a diagnosis of multiple sclerosis, systemic lupus erythematous, rheumatoid arthritis, Crohn's disease, type 1 diabetes or endometriosis\n* migraine group : with a diagnosis of migraine with at least 4 headache days per month\n\nExclusion Criteria:\n\n* BMI \\\u003C or = 17 ou \\> or = 30kg\u002Fm²\n* type 2 diabetes, immune deficit, other chronic autoimmune or inflammatory disease\n* non-migraine headache, except for tension type headache of less than 4 days\u002Fmonth\n* pregnancy, delivery, miscarriage, breast-feeding, participation in a medically assisted human reproduction program (ovary stimulation\u002Fhormone therapy) \\\u003C 3 months before blood sampling\n* Menopause, hysterectomy, or bilateral oophorectomy\n* Hormone therapy (besides contraception and treatment of endometriosis)\n* bone marrow or solid organ transplant\n* guardianship, curatorship, safeguard of justice or deprivation of liberty\n* for patients : diagnosis of several autoimmune or inflammatory diseases\n* for controls : diagnosis of an autoimmune or inflammatory disease\n* for non-migraine participants : migraine","FEMALE","50 Years",{"count":185,"type":20},396,[58],"Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and\u002For inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and endometriosis, whereas patients with long standing type 1 diabetes mellitus (T1DM) - an autoimmune but non inflammatory disease - seem to be less affected compared to the general population. Despite new migraine prevention treatments, a large number of patients remain unresponsive to currently available anti-migraine therapy and migraine pathophysiology remains unclear. Several peptides (calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase activating peptide-38 (PACAP-38), vasoactive intestinal polypeptide (VIP)) and hormones (estrogens, prolactin) and the immune system play an important role in migraine pathophysiology. Among T lymphocytes, regulatory T (Treg) cells suppress inflammation. Studies have evidenced higher levels of inflammatory molecules (cytokines) in migraine patients and have suggested decreased proportions of Treg cells in migraine, as well as in MS, RA, CD and SLE, whereas inflammation declines and Treg levels seem increased in long-standing T1DM. Inflammation, which participates in migraine pain, seems to be a common factor for migraine and these diseases. However, these studies display conflicting results and further investigation is required to better understand the mechanisms behind migraine.\n\nIn this study, the investigators will compare Treg levels, as well as identify Treg subpopulations and measure cytokine levels in migraine and migraine-free participants with and without an autoimmune\u002Finflammatory disorder (MS, RA, CD, SLE, T1DM and endometriosis).",[189,190,191,192,193,194,195,27],"Migraine Disorders","Pain","Autoimmune Diseases","Multiple Sclerosis","Endometriosis","Rheumatoid Arthritis","Crohn Disease",[189,190,197,198],"Cytokines","Regulatory T cell","2025-11-17",{"date":165,"type":37},{"date":202,"type":37},"2025-06-02",{"date":204,"type":20},"2027-04-30",{"name":206,"class":44},"University Hospital, Clermont-Ferrand",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":45},"100337461","phase-2-treatment-of-lupus-nephritis-with-allogeneic-mesenchymal-stem-cells-100337461","NCT03673748","Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells","Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus Nephritis","MSV_LE","INCLUSION CRITERIA:\n\n1. Females or males ≥18 years old who provide written informed consent at the selection visit.\n2. Diagnosis of systemic lupus erythematosus (SLE) by meeting at least 4 of the 11 criteria included in the American College of Rheumatology (ACR) classification and\u002For the Systemic Lupus International Collaborating Clinics (SLICC) criteria, at the selection visit.\n3. Diagnosis of lupus nephritis (LN) using the 2003 classification of the International Society of Nephrology and the Society of Renal Pathology, by biopsy performed no more than 6 months before the selection visit if they enter from the induction period, and no more than one year if they enter with a moderate\u002Fsevere recurrence.\n4. No response or partial response to standard treatment, or moderate\u002Fsevere recurrence of lupus nephritis.\n5. SLEDAI-2K ≥ 10 during the selection period.\n6. Women of childbearing potential should use effective methods of contraception to prevent pregnancy.\n7. Have been vaccinated against pneumococcus and influenza at the time the vaccination campaign is carried out.\n\nEXCLUSION CRITERIA:\n\nA - Related to previous treatments:\n\n1. Use of corticosteroids or mycophenolate above the doses allowed for induction, according to the Consensus Document of the Systemic Autoimmune Diseases Group of the Spanish Society of Internal Medicine and the Spanish Society of Nephrology.\n2. Use of rituximab, belimumab, ocrelizumab or other biologic therapies against B cells in the 6 months prior to selection.\n3. Use of cyclophosphamide in the 6 months prior to selection.\n4. Use of any tumor necrosis factor inhibitor treatment in the 6 months prior to selection.\n5. Use of immunoglobulins in the 6 months prior to selection.\n6. Change in doses of an angiotensin converting enzyme inhibitor or an angiotensin receptor inhibitor in the two months prior to selection.\n7. Treatment with another investigational medicinal product within three months prior to selection or 5 times the half-life of the agent.\n\n   B - Related to medical problems:\n8. Any pathology, including an uncontrolled disease other than SLE, which, in the opinion of the investigator, the sponsor or the person they designate, constitutes an inappropriate risk or a contraindication for participation in the trial or that could interfere with the objectives of the trial, its performance or evaluation.\n9. Cardiac, peripheral, or cerebrovascular cardiovascular events in the 6 months prior to the selection visit.\n10. Active cardiac arrhythmia or clinically significant electrocardiogram abnormalities at selection visit or on the day of randomization that, in the opinion of the investigator, sponsor, or designee, constitute an inappropriate risk or contraindication to participation in the study.\n11. Thromboembolic events in the 12 months prior to or during selection, whether or not associated with associated antiphospholipid syndrome, or inadequate anticoagulation tests 6 weeks immediately prior to or during selection visit.\n12. Active central nervous system SLE that is considered severe or progressive (recent uncontrolled seizures, changes in anticonvulsant treatment within 3 months prior to selection visit, or resulting in significant cognitive impairment).\n13. History or current diagnosis of a demyelinating disease such as multiple sclerosis or optic neuritis.\n14. Comorbidities that require treatment with systemic corticosteroids (oral, rectal or injectable) such as asthma or inflammatory bowel disease.\n15. Antecedents or plans for an organ transplant.\n16. Clinically significant active viral, bacterial or fungal infection, or having suffered a major episode of infection that required hospitalization or parenteral treatment in the 4 weeks prior to the selection visit, during the selection visit, or having finished anti-infective treatment within 2 weeks prior to or during selection, or a history of recurrent infections (three or more cases of the same type of infection in a consecutive 12-month period). Controlled vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus would not be reasons for exclusion.\n17. History of or positive human immunodeficiency virus (HIV) test result, hepatitis C antibodies and\u002For detection by polymerase chain reaction, hepatitis B surface antigen (HBsAg+), and\u002For IgM or total antibodies against hepatitis B nuclear antigen at selection.\n18. Diagnosis of active or latent tuberculosis (TB) using a purified protein derivative TB skin test (induration ≥ 5 mm) or a positive Quantiferon test result, at selection or within 3 months prior to the selection visit. Patients who have completed previous adequate treatment or who are receiving treatment will not repeat the test. Patients who are receiving adequate TB treatment for at least 4 continuous weeks prior to the selection visit and who are expected to complete the treatment regimen will not be excluded.\n19. Presence of class 3 or 4 uncontrolled congestive heart failure according to the New York Heart Association.\n20. Active cancer.\n21. Major surgical intervention within 6 weeks prior to selection visit or planned during the trial period, including follow-up.\n22. Pregnant or lactating women.\n\n    C - Laboratory abnormalities:\n23. Clinically significant laboratory test abnormalities not attributed to active SLE.\n24. Chest X-ray with significant changes indicating active TB. The chest X-ray must have been performed within 3 months prior to the selection visit or during the selection period.\n\n    D - Others:\n25. Legal incapacity.",{"count":216,"type":20},20,[218],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.",[221,27],"Lupus Nephritis",[27,221,223,224,225,226],"Stem Cell","Mesenchymal Stem Cells","Autoimmune diseases","Systemic Lupus Erythematosus","2025-07-21",{"date":229,"type":37},"2025-07-24",{"date":231,"type":37},"2022-12-27",{"date":233,"type":20},"2027-12",{"name":235,"class":236},"Red de Terapia Celular","INDUSTRY"]